Clinical trials: Diabetes, Type 1
Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study
This study will evaluate the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Diabetes, Gestational
- Trial name
- NCT07889388
- Testing
- RIGHTEST iFree 2 Continuous Glucose Monitoring System
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- Bionime Corporation
Type 2 Diabetes Mellitus
Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus
The purpose of this study is to compare the efficacy of Amaryl®M 1/500 mg twice daily versus Amaryl® 4 mg both in combination with Lantus® once-daily regimen in type 2 Diabetes Mellitus patients with inadequate glycemic control.
- Trial name
- NCT00913367
- Testing
- glimepiride + insulin glargine (Amaryl + Lantus), glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
A Continuous Glucose Monitor Based Insulin Bolus Calculator
This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor
- Trial name
- CGM-IBC (NCT05229445)
- Testing
- continuous glucose monitor based insulin bolus calculator
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Welldoc
Type 1 Diabetes Mellitus
Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the dose-response pattern of the glucose consumption (GIR-AUC0-end) of 3 different single doses of Afrezza inhaled Technosphere insulin and of 3 single doses of subcutaneous (SC) insulin lispro in a…
- Trial name
- NCT02470637
- Testing
- SAR439065, Insulin lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus in Obese, Obesity
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes
- Trial name
- NCT05409027
- Testing
- SPI-62, Cortisone-d8
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sparrow Pharmaceuticals
Type 1 Diabetes Mellitus (T1DM)
Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil
Multi-centre, open label, multiple ascending dose trial in patients with type 1 diabetes mellitus
- Trial name
- NCT04141423
- Testing
- Tregopil
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Biocon Limited
Diabetes, Diabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes.
- Trial name
- DUAL™ I (NCT01336023)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,663 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1
The aim of this trial is to compare the pharmacokinetics and pharmacodynamics of insulin lispro injection into either lipohypertrophic lesions or normal tissue, utilizing both state-of-the-art euglycaemic clamp and mixed meal…
- Trial name
- NCT02221323
- Testing
- Insulin LISPRO
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
T2DM
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled, single-dose escalation trial was designed. There are 6 dose groups and 1 optional dose group: 0.5 mg, 2 mg, 8 mg, 25mg, 50 mg, 100 mg and 150 mg (optional).
- Trial name
- NCT05996380
- Testing
- SHR-3167
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes, Diabetes Mellitus, Type 1
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01900834
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00665093
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,569 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 1 Diabetes Mellitus
Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D
Feasibility study to evaluate the safety and feasibility of Omnipod automated insulin delivery algorithms in individuals with type 1 diabetes.
- Conditions
- Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes (DM)
- Trial name
- EVOLUTIONT1D (NCT07593625)
- Testing
- Omnipod M System, Omnipod S
- Where
- New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Insulet Corporation
Type 2 Diabetes Mellitus
Absolute Bioavailability Study With Bexagliflozin
The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.
- Trial name
- NCT03417076
- Testing
- Bexagliflozin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Theracos
Diabetes Mellitus
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes
This study will determine 1) the safety of AC2993 in patients with type I diabetes; 2) the ability of AC2993 to improve beta cell function; and 3) the effects of immunosuppression on beta cell function.
- Trial name
- NCT00064714
- Testing
- AC2993 (exenatide), daclizumab (immunosuppressive)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
In Clinic Evaluation of the PLGM Feature
This study is a multi-center, single arm and in-clinic study to evaluate the safety of the PLGM System and its algorithm with the Enlite 3 Sensor.
- Trial name
- PLGM (NCT02130284)
- Testing
- Predictive Low Glucose Management Feature in Insulin pump
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes
This study is testing VV-14299 and VV-14300 or VV-14300 alone in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system.
- Trial name
- PROGRESS (NCT07829302)
- Testing
- VV-14300, VV-14299
- Where
- Australia
- Volunteers
- 29 people
- Sponsor
- Kriya Therapeutics, Inc.
Type 2 Diabetes Mellitus
Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes
The purpose of this clinical trial is to test safety and tolerability of a vaccine targeting Interleukin-1 beta in patients with type 2 diabetes.
- Trial name
- NCT00924105
- Testing
- CYT013-IL1bQb
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 48 people
- Sponsor
- Cytos Biotechnology AG
Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus with Hypoglycemia
A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults with Type-1 Diabetes Mellitus
The primary aim of this study is to assess the feasibility of the Lab demo 1.0 and associated computational models to detect and track glucose changes noninvasively and transcutaneously in defined and dynamic states of glycemia.
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus with Hypoglycemia, Type 1 Diabetes Mellitus with Hyperglycemia
- Trial name
- NCT06097689
- Testing
- Lab Demo 1.0
- Where
- Switzerland
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Liom Health AG
Diabetes Mellitus, Type 1
Insulin Glargine in Type 1 Diabetes Mellitus
The primary purpose of the protocol is to demonstrate that the new regimen (insulin glargine+regular insulin ) is no worse than the reference regimen (insulin glargine+lys-pro insulin ) in reducing the incidence of severe…
- Trial name
- NCT00272090
- Testing
- Insulin glargine
- Volunteers
- 489 people
- Sponsor
- Sanofi
Selected Advanced Solid Tumors
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
- Trial name
- NCT03530397
- Testing
- MEDI5752, Pemetrexed, Carboplatin
- Where
- 40 sites in United States, Australia and 7 more
- Volunteers
- 400 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.